ENLISTING IMMUNE SYSTEM

Results from the largest multi-site study to date evaluating a peptide-derived therapeutic vaccine for melanoma show promising evidence that researchers can activate a patient's own immune system to fight advanced melanoma.

Related Videos
Related Content

Lebrikizumab Demonstrates Promising Results in Atopic Dermatitis

March 24th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Highlights from AAD 2023

March 23rd 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

New Technology Could Allow Us to Rethink Alopecia Scores

March 23rd 2023

Upadacitinib Advances to Phase 3 Clinical Trials in Systemic Lupus Erythematosus

March 23rd 2023

Lebrikizumab Demonstrates Promising Results in Atopic Dermatitis

March 24th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Highlights from AAD 2023

March 23rd 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

New Technology Could Allow Us to Rethink Alopecia Scores

March 23rd 2023

Upadacitinib Advances to Phase 3 Clinical Trials in Systemic Lupus Erythematosus

March 23rd 2023

Lebrikizumab Demonstrates Promising Results in Atopic Dermatitis

March 24th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Highlights from AAD 2023

March 23rd 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

New Technology Could Allow Us to Rethink Alopecia Scores

March 23rd 2023

Upadacitinib Advances to Phase 3 Clinical Trials in Systemic Lupus Erythematosus

March 23rd 2023
© 2023 MJH Life Sciences

All rights reserved.